{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:59:46Z","timestamp":1790827186298,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.radonc.2024.110461","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T11:10:04Z","timestamp":1721992204000},"page":"110461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Risk of radionecrosis in HER2-positive breast cancer with brain metastasis receiving trastuzumab emtansine (T-DM1) and brain stereotactic radiosurgery"],"prefix":"10.1016","volume":"199","author":[{"given":"Seok-Joo","family":"Chun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6093-1294","authenticated-orcid":false,"given":"Kyubo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Bae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Ha","family":"Paek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Hun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ho","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Il","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Salvestrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1861-2895","authenticated-orcid":false,"given":"Icro","family":"Meattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Livi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Hwan","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2024.110461_b0005","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110461_b0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2019.11.001","article-title":"Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort","volume":"125","author":"Pasquier","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2024.110461_b0015","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","article-title":"The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis","volume":"23","author":"Kuksis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.radonc.2024.110461_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13122927","article-title":"Brain metastases in her2-positive breast cancer: Current and novel treatment strategies","volume":"13","author":"Garcia-Alvarez","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2024.110461_b0025","article-title":"How we treat patients with metastatic HER2-positive breast cancer","volume":"7","author":"Nader-Marta","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.radonc.2024.110461_b0030","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.breast.2018.07.004","article-title":"T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer","volume":"41","author":"Fabi","year":"2018","journal-title":"Breast"},{"key":"10.1016\/j.radonc.2024.110461_b0035","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.annonc.2020.06.020","article-title":"Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial\u2606","volume":"31","author":"Montemurro","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2024.110461_b0040","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10549-016-3828-6","article-title":"Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases","volume":"157","author":"Jacot","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.radonc.2024.110461_b0045","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","volume":"18","author":"Di\u00e9ras","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2024.110461_b0050","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2024.110461_b0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/annonc\/mdu486","article-title":"Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: A retrospective, exploratory analysis in EMILIA","volume":"26","author":"Krop","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2024.110461_b0060","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer \u2606","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2024.110461_b0065","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Breast Cancer. Natl Compr Cancer Netw 2023;4. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf (accessed May 5, 2023)."},{"key":"10.1016\/j.radonc.2024.110461_b0070","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Central Nervous Sytem Cancers, Natl Compr Cancer Netw 2023;4. (assessed at May 5, 2023) doi:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cns.pdf10.6004\/jnccn.2008.0037."},{"key":"10.1016\/j.radonc.2024.110461_b0075","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO\u2013ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours \u2606","volume":"32","author":"Le Rhun","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2024.110461_b0080","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/neuonc\/not329","article-title":"Trastuzumab emtansine and stereotactic radiosurgery: An unexpected increase in clinically significant brain edema","volume":"16","author":"Carlson","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.radonc.2024.110461_b0085","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11060-022-04055-y","article-title":"Trastuzumab emtansine increases the risk of stereotactic radiosurgery-induced radionecrosis in HER2 + breast cancer","volume":"159","author":"Id Said","year":"2022","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2024.110461_b0090","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1158\/1078-0432.CCR-18-2851","article-title":"Combination of trastuzumab emtansine and stereotactic radiosurgery results in high rates of clinically significant radionecrosis and dysregulation of aquaporin-4","volume":"25","author":"Stumpf","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2024.110461_b0095","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11060-016-2265-z","article-title":"Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer","volume":"131","author":"Geraud","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2024.110461_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109805","article-title":"Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis","volume":"186","author":"Salvestrini","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2024.110461_b0105","first-page":"26","article-title":"Symptomatic Necrosis With Antibody-Drug Conjugates and Concurrent Stereotactic Radiotherapy for Brain Metastases","volume":"171","author":"Lebow","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2024.110461_b0110","doi-asserted-by":"crossref","DOI":"10.1007\/s11060-024-04681-8","article-title":"Impact of concurrent antibody\u2013drug conjugates and radiotherapy on symptomatic radiation necrosis in breast cancer patients with brain metastases: a multicenter retrospective study","author":"Koide","year":"2024","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2024.110461_b0115","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMct0806951","article-title":"Stereotactic radiosurgery for the treatment of brain metastases","volume":"362","author":"Suh","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2024.110461_b0120","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0360-3016(99)00507-6","article-title":"Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90\u201305","volume":"47","author":"Shaw","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110461_b0125","article-title":"Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases","volume":"21","author":"Mills","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2024.110461_b0130","first-page":"45","article-title":"Radiation injury of the brain","volume":"12","author":"Valk","year":"1991","journal-title":"Am J Neuroradiol"},{"key":"10.1016\/j.radonc.2024.110461_b0135","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3171\/2010.8.JNS10461","article-title":"Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer","volume":"114","author":"Kondziolka","year":"2011","journal-title":"J Neurosurg"},{"key":"10.1016\/j.radonc.2024.110461_b0140","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/cncr.20167","article-title":"Stereotactic Radiosurgery for Multiple Brain Metastases from Breast Carcinoma: Feasibility and Outcome of a Local Treatment Concept","volume":"100","author":"Muacevic","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2024.110461_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djv313","article-title":"Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment","volume":"108","author":"Askoxylakis","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2024.110461_b0150","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.radonc.2017.08.006","article-title":"Blood\u2013tumor barrier opening changes in brain metastases from pre to one-month post radiation therapy","volume":"125","author":"Teng","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2024.110461_b0155","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ijrobp.2005.01.039","article-title":"Molecular targets in radiation-induced blood-brain barrier disruption","volume":"62","author":"Nordal","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110461_b0160","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC\u2013ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402400731X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402400731X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T05:49:03Z","timestamp":1729057743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016781402400731X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":32,"alternative-id":["S016781402400731X"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110461","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of radionecrosis in HER2-positive breast cancer with brain metastasis receiving trastuzumab emtansine (T-DM1) and brain stereotactic radiosurgery","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110461","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110461"}}